Myopia Control: New Guidelines to Protect Your Child's Vision
"Expert recommendations help parents make informed decisions about managing myopia and preventing long-term eye health risks."
Myopia, or nearsightedness, is a common vision problem affecting millions of children worldwide. While easily corrected with glasses or contacts, in some children, myopia progresses rapidly, leading to high myopia, a condition that significantly increases the risk of severe eye diseases such as maculopathy, cataracts, and glaucoma. This is why taking proactive steps to manage myopia early on is so important.
Orthokeratology (ortho-k) has emerged as a promising method for slowing down myopia progression in children. This involves wearing specially designed rigid lenses overnight to reshape the cornea and temporarily reduce nearsightedness. While studies have shown ortho-k's effectiveness, it's not a one-size-fits-all solution. Determining which children will benefit most requires careful evaluation.
Now, new research from Hong Kong provides evidence-based guidelines to help eye care professionals identify the best candidates for myopia control using ortho-k. These guidelines consider a child's age, rate of myopia progression, and other factors to ensure the benefits of ortho-k outweigh potential risks.
Why Early Myopia Control Matters
A 2023 meta-analysis notes that controlling myopia in school-age children is important to reduce the future incidence of severe myopia. It also reports that orthokeratology studies vary in follow-up duration, research design, and participant characteristics, complicating comparisons across the evidence. A separate analysis pooled data from three prospective studies comparing children using orthokeratology with children wearing distance single-vision spectacles over two years. These sources describe the research context but do not provide a population-wide prevalence estimate.
From Correction to Active Management
The clinical approach to myopia has shifted from passive optical correction toward strategies intended to prevent onset and slow axial elongation. Common approaches to slowing progression include optical, pharmacological, and behavioral methods. A 2024 systematic review and meta-analysis examined orthokeratology’s risks and benefits compared with other myopia-control methods in children and adults, searching Cochrane Central Register of Controlled Trials, PubMed, Embase, and Ovid through August 22, 2021. The supplied source summaries do not specify particular comparative risks or limitations, so these should not be inferred from the review’s scope alone.
Is Your Child at Risk? Understanding Myopia Progression
The study, published in Contact Lens and Anterior Eye, followed 66 myopic children (aged 6-16) who wore single-vision glasses for seven months before switching to ortho-k lenses for another seven months. Researchers tracked changes in axial elongation (AE), the lengthening of the eye that contributes to myopia progression.
- Rapid Progression: AE of ≥0.20 mm in seven months (equivalent to ≥1.00 D increase in myopia per year)
- Moderate Progression: AE between 0.10 mm and <0.20 mm in seven months (equivalent to 0.50 D to <1.00 D increase in myopia per year)
- Slow Progression: AE of <0.10 mm in seven months (equivalent to <0.50 D increase in myopia per year)
Recent Studies and Monitoring
A prospective study of overnight orthokeratology in patients with moderate myopia and astigmatism reported that 7.02% achieved 6/6 vision by the first follow-up, rising to 85.11% by Day 90. A separate study on categorizing progression by refractive error and axial elongation suggests that people with slow progression by both measures would not be candidates for immediate therapy under previously published guidelines, while continued monitoring remains important because progression rates can vary over the years. A pediatric contact-lens safety scoping review included 73 studies from 10 countries, covering children aged 6 to 18 and primarily orthokeratology and soft contact lenses.
Evidence and Limits of the Case for Ortho-K
The ROMIO study was a two-year randomized clinical trial, and 78 subjects completed it: 37 in the orthokeratology group and 41 in the control group. A separate review describes numerous peer-reviewed studies as showing that orthokeratology can slow myopic progression, while tracing its development from a refractive option toward a myopia-control approach. These summaries support discussing both trial evidence and broader published experience, but they do not provide enough information to quantify failure rates or establish that treatment works for every child.
Axial-Length Outcomes in Comparisons
A systematic review and meta-analysis reported a statistically significant two-year difference in axial-length change between orthokeratology and control groups, with a weighted mean difference of −0.25 mm (95% CI, −0.30 to −0.21). In a study of Chinese children, axial length increased more in the control group than in the orthokeratology group at both 12 months (0.39 ± 0.21 mm versus 0.16 ± 0.17 mm) and 24 months (0.70 ± 0.35 mm versus 0.34 ± 0.29 mm); both comparisons had p < 0.001. Another study found increases of 0.10 ± 0.10 mm in the orthokeratology group and 0.20 ± 0.11 mm in the spectacle group (P < 0.001), while anterior segment length did not appreciably change in either group. A 2023 update reported that most surveyed eyecare practitioners considered orthokeratology the most effective myopia-control monotherapy, but that is a report of practitioner attitudes, not a head-to-head result against DIMS lenses.
Making Informed Decisions: A Guide for Parents
These new guidelines offer a valuable framework for eye care professionals to assess a child's risk of myopia progression and determine if ortho-k is the right choice. If you're concerned about your child's vision, talk to your eye doctor about these recommendations. Early intervention and personalized management plans can make a significant difference in protecting your child's long-term eye health and quality of life.
Mechanisms Still Under Discussion
The mechanisms by which orthokeratology slows myopia progression remain in contention. Proposed factors that may regulate axial elongation include peripheral defocus, increased corneal higher-order aberrations, and choroidal thickening. These are presented as postulated mechanisms rather than settled explanations, so the source does not establish which factor is responsible or how much each contributes.
Market Trends and Remote Care
A market report says telemedicine integration with orthokeratology services can improve patient access and operational efficiency through remote consultations and monitoring. It also reports that myopia accounted for 72% of the orthokeratology market by application in 2024. Another source describes expected sustained growth in the orthokeratology lens market from 2026 to 2034, while a market analysis notes that myopia-control lens options include multifocal, dual-focus, and orthokeratology designs. These are market and trend reports, not clinical evidence that a particular lens or remote-care model improves treatment outcomes.
Individualized Care in Practice
A real-world study evaluated myopia-control spectacles and orthokeratology in children with intermittent exotropia, examining myopia progression and binocular function in routine clinical practice. A case study describes a practitioner who considered orthokeratology challenging and time-consuming because of the child’s high prescription and flat corneas, and discussed adding a second treatment. The supplied summaries illustrate why treatment selection and adjustment may be individualized, but they do not provide comparative outcome figures for these cases. They also mention healthy nutrition and adequate sleep as topics discussed in that case, without establishing their effects.